This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Study of Lenalidomide to Evaluate Safety and Efficacy in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Celgene
ClinicalTrials.gov Identifier:
NCT00963105
First received: August 20, 2009
Last updated: May 10, 2017
Last verified: May 2017
August 20, 2009
May 10, 2017
October 19, 2009
September 11, 2017   (Final data collection date for primary outcome measure)
Safety [type, frequency, and severity of adverse events (AEs) and relationship of AEs to lenalidomide] [ Time Frame: up to 55 months ]
Number, type, frequency, and severity of adverse events (AEs) and treatment emergent adverse events associated to lenalidomide
Safety [type, frequency, and severity of adverse events (AEs) and relationship of AEs to lenalidomide] [ Time Frame: 24 months post LPFV ]
Complete list of historical versions of study NCT00963105 on ClinicalTrials.gov Archive Site
  • Response rate (RR); International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Guidelines for diagnosis and treatment of CLL [ Time Frame: up to 55 months ]
    Best response during the treatment period will be assessed by the IwCLL guidelines for diagnosis and treatment of CLL (Hailek, 2008)
  • Duration of response (DOR) [ Time Frame: up to 55 months ]
    The duration of response is defined as the time from first visit or at least partial response was documented until PD.
  • Time to response (TTR) [ Time Frame: up to 55 months ]
    Time to first response is calculated as the time from randomization to the first document date of at least partial response
  • Time to progression (TTP) [ Time Frame: up to 55 months ]
    TTP is defined as the time from randomization to the first documented progression.
  • Event-Free survival (EFS) [ Time Frame: up to 55 months ]
    EFS is the interval between the start of treatment to the first sign of disease progression, or treatment for relapse or death (whichever comes first)
  • Progression Free survival (PFS) [ Time Frame: up to 55 months ]
    PFS is defined as the time randomization to the first observation of disease progression or death due to any cause during or after the treatment period, whichever occurs first.
  • Overall Survival (OS) [ Time Frame: up to 55 months ]
    Overall survival (OS) was defined as the time from randomization to death of any cause.
  • Response rate [per the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Guidelines for diagnosis and treatment of CLL (Hallek, 2008)] [ Time Frame: 24 months post LPFV ]
  • Duration of response, Time to response, Time to progression, Event-free survival, Progression-free survival, Overall survival [ Time Frame: 24 months post LPFV ]
Not Provided
Not Provided
 
Study of Lenalidomide to Evaluate Safety and Efficacy in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
A Phase 2, Multi-Center, Randomized, Double-Blinded, Parallel Group Study of the Safety and Efficacy of Different Lenalidomide Dose Regimens in Subjects With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia
The purpose of this study is to determine the safety and effectiveness of different dose regimen of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia.
Not Provided
Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Participant, Care Provider, Investigator, Outcomes Assessor
Primary Purpose: Treatment
Relapsed or Refractory Chronic Lymphocytic Leukemia
Drug: lenalidomide

Depending on the starting dose, subjects will be allocated in a double-blind fashion to three different regimens and will escalate every 28 days, based on individual subject tolerability, as follows:

  • Treatment Arm 1: 5 mg →10 mg →15 mg →20 mg →25 mg/daily
  • Treatment Arm 2: 10 mg →15 mg →20 mg →25 mg/daily
  • Treatment Arm 3: 15 mg →20 mg →25 mg/daily Subjects will continue treatment until disease progression or unacceptable toxicity
  • Active Comparator: Treatment Arm 1

    Treatment Arm 1: 5 mg →10 mg →15 mg →20 mg →25 mg/daily

    Subjects will continue treatment until disease progression or unacceptable toxicity

    Intervention: Drug: lenalidomide
  • Active Comparator: Treatment Arm 2

    Treatment Arm 2: 10 mg →15 mg →20 mg →25 mg/daily

    Subjects will continue treatment until disease progression or unacceptable toxicity

    Intervention: Drug: lenalidomide
  • Active Comparator: Treatment Arm 3

    Treatment Arm 3: 15 mg →20 mg →25 mg/daily

    Subjects will continue treatment until disease progression or unacceptable toxicity

    Intervention: Drug: lenalidomide

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
104
September 11, 2017
September 11, 2017   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Age ≥ 18 years at the time of signing the informed consent form
  • Must be able to adhere to the study visit schedule and other protocol requirements
  • Must have a documented diagnosis of B-cell CLL
  • Must be relapsed or refractory to at least 1 regimen for treatment of CLL . At least one of the prior treatments must have included a purine analog-based or bendamustine-based regimen
  • Must have an Eastern Cooperative Oncology Group (ECOG) performance status score of ≤2.

Exclusion Criteria:

  • Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form
  • Active infections requiring systemic antibiotics
  • Systemic treatment for B-cell CLL within 28 days of initiation of lenalidomide treatment
  • Alemtuzumab therapy within 120 days of initiating lenalidomide treatment
  • Prior therapy with lenalidomide
  • History of grade 4 rash due to prior thalidomide treatment
  • Planned autologous or allogeneic bone marrow transplantation
  • Central nervous system (CNS) involvement as documented by spinal fluid cytology or imaging.
  • Uncontrolled hyperthyroidism or hypothyroidism
  • Venous thromboembolism within 12 months
  • ≥ Grade-2 neuropathy
  • Uncontrolled autoimmune hemolytic anemia or thrombocytopenia
  • Disease transformation [i.e. Richter's Syndrome (lymphomas) or prolymphocytic leukemia]
  • Participation in any clinical study or having taken any investigational therapy within 28 days prior to initiating lenalidomide therapy
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Canada,   France,   Germany,   Italy,   Spain,   Sweden,   United Kingdom,   United States
 
 
NCT00963105
CC-5013-CLL-009
Yes
Not Provided
Not Provided
Not Provided
Celgene
Celgene
Not Provided
Study Director: Kenichi Takeshita, M.D., MPH Celgene Corporation
Celgene
May 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP